Novo Nordisk A/S, which claims 27% of the global market for diabetes care, reported a 24% increase in sales in the 2015 first quarter to DKK 25.2 billion (€3.4 billion) while its operating profit soared by 73% to DKK 13.9 billion. ---Subscribe to MedNous to access this article--- Company News
